SCHEMBL2325910

SCHEMBL2325910

CC[C@@H](O)C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL820467 1.00
SCHEMBL5354435 1.00
Hydrochloric Acid SCHEMBL2413368 0.97
Methylamine SCHEMBL27403434 0.97 CA1 (0.41)
SCHEMBL8097160 0.85 MAPT (0.36)
SCHEMBL5583603 0.82 ALOX15 (0.34)
SCHEMBL15648928 0.82 EPHX1 (0.34)
Hydrochloric Acid SCHEMBL15648597 0.80 GNAI3 (0.34)
SCHEMBL294878 0.78
SCHEMBL4107937 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12344618-B2 Heterotricyclic derivative compound and use of same HANMI PHARMACEUTICAL CO., LTD. (KR) 2025-07-01 US claimed
US-20220135582-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME HANMI PHARMACEUTICAL CO., LTD. (KR) 2022-05-05 US claimed
EP-3929199-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME Hanmi Pharmaceutical Co., Ltd. (KR) 2021-12-29 EP claimed
CN-113423710-A Novel heterocyclic tricyclic derivative compound and use thereof 韩美药品株式会社 2021-09-21 CN claimed
US-12344618-B2 Heterotricyclic derivative compound and use of same HANMI PHARMACEUTICAL CO., LTD. (KR) 2025-07-01 US disclosed
CN-113423710-B Novel heterocyclic tricyclic derivative compounds and use thereof 韩美药品株式会社 2024-06-14 CN disclosed
US-20220135582-A1 NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME HANMI PHARMACEUTICAL CO., LTD. (KR) 2022-05-05 US disclosed
CN-113423710-A Novel heterocyclic tricyclic derivative compound and use thereof 韩美药品株式会社 2021-09-21 CN disclosed
EP-2753606-B1 PYRIMIDINES AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA LP (US) 2017-07-05 EP disclosed
US-9656968-B2 Pyrimidines as sodium channel blockers PURDUE PHARMA L.P. 2017-05-23 US disclosed
US-9586931-B2 Triazolyl derivatives as Syk inhibitors MERCK SHARP & DOHME CORP. (US) 2017-03-07 US disclosed
US-20160024022-A1 PYRIMIDINES AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA L.P. (US) 2016-01-28 US disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 US disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 US disclosed
US-7279304-B2 Methods for preparation of macrocyclic molecules and macrocyclic molecules prepared thereby PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-10-09 US disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 EP disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 EP disclosed
US-20020192773-A1 Methods for preparation of macrocyclic molecules and macrocyclic molecules prepared thereby THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2002-12-19 US disclosed
US-20020042055-A1 Alteration of hydrolase genes and screening of the resulting libraries for the ability to catalyze specific reactions MAXYGEN, INC. 2002-04-11 US disclosed
WO-2001046476-A1 ALTERATION OF HYDROLASE GENES AND SCREENING OF THE RESULTING LIBRARIES FOR THE ABILITY TO CATALYZE SPECIFIC REACTIONS MAXYGEN, INC. (US) 2001-06-28 WO disclosed